157 related articles for article (PubMed ID: 34315764)
1. Preclinical and Early Clinical Development of PTC596, a Novel Small-Molecule Tubulin-Binding Agent.
Jernigan F; Branstrom A; Baird JD; Cao L; Dali M; Furia B; Kim MJ; O'Keefe K; Kong R; Laskin OL; Colacino JM; Pykett M; Mollin A; Sheedy J; Dumble M; Moon YC; Sheridan R; Mühlethaler T; Spiegel RJ; Prota AE; Steinmetz MO; Weetall M
Mol Cancer Ther; 2021 Oct; 20(10):1846-1857. PubMed ID: 34315764
[TBL] [Abstract][Full Text] [Related]
2. The combination of the tubulin binding small molecule PTC596 and proteasome inhibitors suppresses the growth of myeloma cells.
Nagai Y; Mimura N; Rizq O; Isshiki Y; Oshima M; Rizk M; Saraya A; Koide S; Nakajima-Takagi Y; Miyota M; Chiba T; Oshima-Hasegawa N; Muto T; Tsukamoto S; Mitsukawa S; Takeda Y; Ohwada C; Takeuchi M; Iseki T; Nakaseko C; Lennox W; Sheedy J; Weetall M; Yokote K; Iwama A; Sakaida E
Sci Rep; 2021 Jan; 11(1):2074. PubMed ID: 33483574
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Safety of PTC596, a Novel Tubulin-Binding Agent, in Subjects With Advanced Solid Tumors.
Shapiro GI; O'Mara E; Laskin OL; Gao L; Baird JD; Spiegel RJ; Kaushik D; Weetall M; Colacino J; O'Keefe K; Branstrom A; Goodwin E; Infante J; Bedard PL; Kong R
Clin Pharmacol Drug Dev; 2021 Aug; 10(8):940-949. PubMed ID: 33440067
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of the novel tubulin polymerization inhibitor PTC-028 for myelodysplastic syndrome.
Zhong C; Kayamori K; Koide S; Shinoda D; Oshima M; Nakajima-Takagi Y; Nagai Y; Mimura N; Sakaida E; Yamazaki S; Iwano S; Miyawaki A; Ito R; Tohyama K; Yamaguchi K; Furukawa Y; Lennox W; Sheedy J; Weetall M; Iwama A
Cancer Sci; 2020 Dec; 111(12):4336-4347. PubMed ID: 33037737
[TBL] [Abstract][Full Text] [Related]
5. Effective Delivery of a Microtubule Polymerization Inhibitor Synergizes with Standard Regimens in Models of Pancreatic Ductal Adenocarcinoma.
Eberle-Singh JA; Sagalovskiy I; Maurer HC; Sastra SA; Palermo CF; Decker AR; Kim MJ; Sheedy J; Mollin A; Cao L; Hu J; Branstrom A; Weetall M; Olive KP
Clin Cancer Res; 2019 Sep; 25(18):5548-5560. PubMed ID: 31175095
[TBL] [Abstract][Full Text] [Related]
6. The anti-mitotic agents PTC-028 and PTC596 display potent activity in pre-clinical models of multiple myeloma but challenge the role of BMI-1 as an essential tumour gene.
Bolomsky A; Muller J; Stangelberger K; Lejeune M; Duray E; Breid H; Vrancken L; Pfeiffer C; Hübl W; Willheim M; Weetall M; Branstrom A; Zojer N; Caers J; Ludwig H
Br J Haematol; 2020 Sep; 190(6):877-890. PubMed ID: 32232850
[TBL] [Abstract][Full Text] [Related]
7. 6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability.
Du S; Sarver JG; Trabbic CJ; Erhardt PW; Schroering A; Maltese WA
Cancer Chemother Pharmacol; 2019 Feb; 83(2):237-254. PubMed ID: 30426158
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and biological evaluation of a novel tubulin inhibitor 7a3 targeting the colchicine binding site.
Lai Q; Wang Y; Wang R; Lai W; Tang L; Tao Y; Liu Y; Zhang R; Huang L; Xiang H; Zeng S; Gou L; Chen H; Yao Y; Yang J
Eur J Med Chem; 2018 Aug; 156():162-179. PubMed ID: 30006162
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of (2E,5Z)-5-(2-hydroxybenzylidene)-2-((4-phenoxyphenyl)imino) thiazolidin-4-one, a novel microtubule-depolymerizing agent, in U87MG human glioblastoma cells and corresponding mouse xenograft model.
Zhang Q; Liu X; Li X; Li C; Zhou H; Yan B
J Pharmacol Sci; 2013; 122(3):223-31. PubMed ID: 23877018
[TBL] [Abstract][Full Text] [Related]
10. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
[TBL] [Abstract][Full Text] [Related]
11. The effects of the oral, pan-VEGF-R kinase inhibitor CEP-7055 and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice.
Jones-Bolin S; Zhao H; Hunter K; Klein-Szanto A; Ruggeri B
Mol Cancer Ther; 2006 Jul; 5(7):1744-53. PubMed ID: 16891460
[TBL] [Abstract][Full Text] [Related]
12. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
13. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
14. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
15. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
16. Tubulin colchicine site binding agent LL01 displays potent antitumor efficiency both in vitro and in vivo with suitable drug-like properties.
Wu JD; Cui YJ; Zhou YG; Tang LQ; Zhang CM; Liu ZP
Invest New Drugs; 2020 Feb; 38(1):29-38. PubMed ID: 30887253
[TBL] [Abstract][Full Text] [Related]
17. The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.
Bergès R; Tchoghandjian A; Honoré S; Estève MA; Figarella-Branger D; Bachmann F; Lane HA; Braguer D
Mol Cancer Ther; 2016 Nov; 15(11):2740-2749. PubMed ID: 27540016
[TBL] [Abstract][Full Text] [Related]
18. A novel bis-indole destabilizes microtubules and displays potent in vitro and in vivo antitumor activity in prostate cancer.
Ahn S; Hwang DJ; Barrett CM; Yang J; Duke CB; Miller DD; Dalton JT
Cancer Chemother Pharmacol; 2011 Feb; 67(2):293-304. PubMed ID: 20383708
[TBL] [Abstract][Full Text] [Related]
19. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
Boichuk S; Galembikova A; Syuzov K; Dunaev P; Bikinieva F; Aukhadieva A; Zykova S; Igidov N; Gankova K; Novikova M; Kopnin P
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641324
[TBL] [Abstract][Full Text] [Related]
20. Identification and optimization of biphenyl derivatives as novel tubulin inhibitors targeting colchicine-binding site overcoming multidrug resistance.
Cheng B; Zhu G; Meng L; Wu G; Chen Q; Ma S
Eur J Med Chem; 2022 Jan; 228():113930. PubMed ID: 34794817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
